Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Ongoing clinical trials of the pleiotropic effects of statins Davignon J; Leiter LAVasc Health Risk Manag 2005[]; 1 (1): 29-40BACKGROUND: The multiple effects (ie, pleiotropic effects of statins) have received increasing recognition and may have clinical applicability across a broad range of cardiovascular and noncardiovascular conditions. OBJECTIVE: To determine the relevance and significance of ongoing clinical trials of the pleiotropic effects of statins, focusing on nonlipid effects. METHOD: Ongoing trials were identified through personal communication, reports presented at scientific meetings (2000-2004), and queries made to AstraZeneca, Bristol-Myers Squibb Co, Merck & Co, Novartis, and Pfizer, manufacturers of the currently marketed statins. Published trials and other source material were identified through electronic searches on MEDLINE (1990-2003), abstract books, and references identified from bibliographies of pertinent articles. Eligible studies were the clinical trials of statins currently under way in which primary or secondary outcomes included the statins' nonlipid (ie, pleiotropic) effect(s). Data were extracted and trial quality was assessed by the authors. RESULTS: Of the 22 ongoing trials of the nonlipid effects of statins identified, 10 assessed inflammatory markers and plaque stabilization, 4 assessed oxidized low density lipoprotein/vascular oxidant stress, 3 assessed end-stage renal disease, 3 assessed fibrinogen/viscosity, 2 assessed endothelial function, 2 assessed acute coronary syndrome, 2 assessed aortic stenosis progression, and 1 each assessed hypertension, osteoporosis, ischemic burden, Alzheimer's disease, multiple sclerosis, and stroke (outcomes often overlapped). CONCLUSION: Given the excellent safety and tolerability of statins as a class, full exploration of their pleiotropic effects has the potential to provide additional benefits to many patients.|Anti-Inflammatory Agents/therapeutic use[MESH]|Anticoagulants/therapeutic use[MESH]|Antioxidants/therapeutic use[MESH]|Aortic Diseases/drug therapy[MESH]|Arthritis, Rheumatoid/drug therapy[MESH]|Atherosclerosis/drug therapy[MESH]|Cardiovascular Diseases/*drug therapy/physiopathology[MESH]|Clinical Trials as Topic/methods[MESH]|Constriction, Pathologic/drug therapy[MESH]|Dementia/drug therapy[MESH]|Endothelium, Vascular/drug effects/physiopathology[MESH]|Heart Failure/drug therapy[MESH]|Humans[MESH]|Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology/*therapeutic use[MESH]|Hypertension/drug therapy[MESH]|Multiple Sclerosis/drug therapy[MESH]|Osteoporosis/drug therapy[MESH]|Research Design[MESH]|Stroke/prevention & control[MESH]|Treatment Outcome[MESH] |